German biotech snaps up struggling Third Rock-founded drugmaker
January 16, 2020 at 11:19 AM EST
The cancer-focused startup is being acquired for $67 million — roughly two-thirds of what the company made in its 2018 IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.